DS
CADX

David Shaw’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

David Shaw’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-102,552
Closed -$928K – 4948
2013
Q4 		$928K Buy
102,552
+49,069
+92% +$354K ﹤0.01% 3241
2013
Q3 		$337K Sell
53,483
-104,262
-66% -$663K ﹤0.01% 3838
2013
Q2 		$1.08M Buy
+157,745
New +$1.1M ﹤0.01% 2648

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

David Shaw's CADX Position: Q1 2014 in Review

David Shaw sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 102,552 shares — an estimated $928K sold.

David Shaw first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $1.08M in Q2 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • David Shaw reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • David Shaw sold 102,552 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $928K.
  • David Shaw first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
  • David Shaw's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $1.08M in Q2 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on D.E. Shaw & Co's 13F filing for Q1 2014, filed 15 May 2014.